Thiogenesis Therapeutics to Present at UMDF's Mitochondrial Medicine 2025 Conference

Dr. Rioux to Highlight Industry-Leading Clinical Programs in MELAS and Leigh Syndrome Spectrum

San Diego, California--(Newsfile Corp. - June 20, 2025) - Thiogenesis Therapeutics, Corp. (TSXV: TTI) (OTCQX: TTIPF) ("Thiogenesis" or the "Company"), a clinical-stage biopharmaceutical company developing sulfur-based therapeutics for rare pediatric and inherited mitochondrial disorders, today announced that its Chief Executive Officer, Patrice Rioux, MD, Ph.D., will participate in a high-profile clinical panel discussion at the United Mitochondrial Disease Foundation's ("UMDF") 2025 Mitochondrial Medicine Conference. The session is scheduled for Friday, June 20, 2025, in St. Louis, Missouri.

The UMDF Mitochondrial Medicine Conference is recognized as the foremost global gathering for mitochondrial disease research, bringing together over 700 leading scientists, clinicians, and industry stakeholders. The conference is a premier platform for showcasing advances in diagnostics, clinical research, and potential therapeutics in mitochondrial medicine.

Dr. Rioux will provide updates on Thiogenesis' two lead Phase 2 clinical programs evaluating its novel thiol drug, TTI-0102:

- A European multicenter trial in patients with Mitochondrial Encephalomyopathy, Lactic Acidosis, and Stroke-like Episodes ("MELAS"), initiated on May 14, 2025

- A U.S.-based trial targeting the Leigh Syndrome Spectrum ("LSS"), following FDA clearance of the Company's Investigational New Drug ("IND") application on June 11, 2025

"I am honored to join my peers at UMDF's Mito Med 2025 to present our promising drug candidate currently in clinical development for two inherited mitochondrial diseases," said Dr. Rioux. "Our lead compound, TTI-0102, a next-generation thiol-based prodrug, is uniquely engineered to enhance intracellular levels of glutathione and taurine-two critical compounds for mitigating oxidative stress, a core pathological driver in mitochondrial disorders."

About UMDF

The United Mitochondrial Disease Foundation's mission is to promote research and education for the diagnosis, treatment and cure of mitochondrial disorders and to provide support to affected individuals and families. For more than 25 years, UMDF has built a network of the top clinicians, hospitals and researchers dedicated to fighting mitochondrial disease. It is driven by a nationwide community of ambassadors solely focused on supporting patients and families affected by mitochondrial disease. UMDF is committed to making a difference by funding the best science no matter where it is found in the world and providing critical programs and services to patients and their families.